Nebulizing poractant alfa versus conventional instillation: Ultrastructural appearance and preservation of surface activity

Pediatric Pulmonology

Volumn 49, Issue 4, 2014, Pages 348-356

  Minocchieri, Stefan ^a,b,c   Knoch, Stephan ^c   Schoel, W Michael ^d   Ochs, Matthias ^e,f,g,h   Nelle, Mathias ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF BERN   (Switzerland)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g German Center for Lung Research   (Germany)

^h Excellence Cluster REBIRTH   (Germany)

Author keywords

aerosol drug therapy; nebulizer; neonatal respiratory distress syndrome; pulmonary surfactant; surface tension

Indexed keywords

PORACTANT; SURFACTANT; BIOLOGICAL PRODUCT; LUNG SURFACTANT; PHOSPHOLIPID;

ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; DRUG INSTILLATION; DRUG STRUCTURE; ENDOTRACHEAL TUBE; LAMELLAR BODY; NEBULIZATION; NEBULIZER; NONHUMAN; PRIORITY JOURNAL; SURFACE TENSION; SWINE; TRANSMISSION ELECTRON MICROSCOPY; VIBRATING MEMBRANE NEBULIZER;

BIOLOGICAL PRODUCTS; INSTILLATION, DRUG; MICROSCOPY, ELECTRON, TRANSMISSION; NEBULIZERS AND VAPORIZERS; PHOSPHOLIPIDS; PULMONARY SURFACTANTS; SURFACE TENSION;

EID: 84896400581     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.22838     Document Type: Article

References (30)

1. Hack M, Wright LL, Shankaran S, Tyson JE, Horbar JD, Bauer CR, Younes N,. Very-low-birth-weight outcomes of the National Institute of Child Health and Human Development Neonatal Network, November 1989 to October 1990. Am J Obstet Gynecol 1995; 172: 457-464.
2. Seger N, Soll R,. Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev 2009; 2: CD007836.
3. Bjorklund LJ, Ingimarsson J, Curstedt T, John J, Robertson B, Werner O, Vilstrup CT,. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 1997; 42: 348-355.
4. Kribs A, Vierzig A, Hunseler C, Eifinger F, Welzing L, Stutzer H, Roth B,. Early surfactant in spontaneously breathing with nCPAP in ELBW infants-A single centre four year experience. Acta Paediatr 2008; 97: 293-298.
5. Avery ME, Tooley WH, Keller JB, Hurd SS, Bryan MH, Cotton RB, Epstein MF, Fitzhardinge PM, Hansen CB, Hansen TN, et al. Is chronic lung disease in low birth weight infants preventable ? A survey of eight centers. Pediatrics 1987; 79: 26-30.
6. Van Marter LJ, Pagano M, Allred EN, Leviton A, Kuban KC,. Rate of bronchopulmonary dysplasia as a function of neonatal intensive care practices. J Pediatr 1992; 120: 938-946.
7. Jorch G, Hartl H, Roth B, Kribs A, Gortner L, Schaible T, Hennecke KH, Poets C,. Surfactant aerosol treatment of respiratory distress syndrome in spontaneously breathing premature infants. Pediatr Pulmonol 1997; 24: 222-224.
8. Mazela J, Merritt TA, Finer NN,. Nebulized surfactants. Curr Opin Pediatr 2007; 19: 155-162.
9. Smedsaas-Lofvenberg A, Nilsson K, Moa G, Axelsson I,. Nebulization of drugs in a nasal CPAP system. Acta Paediatr 1999; 88: 89-92.
10. Pandit PB, Pyon KH, Courtney SE, England SE, Habib RH,. Lung resistance and elastance in spontaneously breathing preterm infants: effects of breathing pattern and demographics. J Appl Physiol 2000; 88: 997-1005.
11. Fok TF, Monkman S, Dolovich M, Gray S, Coates G, Paes B, Rashid F, Newhouse M, Kirpalani H,. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Pediatr Pulmonol 1996; 21: 301-309.
12. Mazela J, Merritt TA, Gadzinowski J, Sinha S,. Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases. Acta Paediatr 2006; 95: 1036-1048.
13. Dubus JC, Vecellio L, De Monte M, Fink JB, Grimbert D, Montharu J, Valat C, Behan N, Diot P,. Aerosol deposition in neonatal ventilation. Pediatr Res 2005; 58: 10-14.
14. Finer NN, Merritt TA, Bernstein G, Job L, Mazela J,., Segal R,. An open label, pilot study of Aerosurf® combined with nCPAP to prevent RDS in preterm neonates. J Aerosol Med Pulm Drug Deliv 2010; 23: 303-309.
15. Dijk PH, Heikamp A, Piers DA, Weller E, Bambang Oetomo S,. Surfactant nebulisation: safety, efficiency and influence on surface lowering properties and biochemical composition. Intensive Care Med 1997; 23: 456-462.
16. Knoch M, Keller M,. The customised electronic nebuliser: a new category of liquid aerosol drug delivery systems. Expert Opin Drug Deliv 2005; 2: 377-390.
17. Scherer T, Geller DE, Owyang L, Tservistas M, Keller M, Boden N, Kesser KC, Shire SJ,. A technical feasibility study of dornase alfa delivery with eFlow® vibrating membrane nebulisers: aerosol characteristics and physicochemical stability. J Pharm Sci 2010; 100: 98-109.
18. Fehrenbach A, Ochs M,. Studying lung ultrastructure. In:, Uhlig S, Taylor AE, editors. Methods in pulmonary research. Basel: Birkhäuser; 1998. pp 429-454.
19. Weibel ER, Hsia CCW, Ochs M,. How much is there really? Why stereology is essential in lung morphometry. J Appl Physiol 2007; 102: 459-467.
20. Ochs M,. A brief update on lung stereology. J Microsc 2006; 222: 188-200.
21. Ochs M, Nenadic I, Fehrenbach A, Albes JM, Wahlers T, Richter J, Fehrenbach H,. Ultrastructural alterations in intraalveolar surfactant subtypes after experimental ischemia and reperfusion. Am J Respir Crit Care Med 1999; 160: 718-724.
22. Ochs M, Schuttler M, Stichtenoth G, Herting E,. Morphological alterations of exogenous surfactant inhibited by meconium can be prevented by dextran. Respir Res 2006; 7: 86.
23. Schurch S, Bachofen H, Goerke J, Possmayer F,. A captive bubble method reproduces the in situ behavior of lung surfactant monolayers. J Appl Physiol 1989; 67: 2389-2396.
24. Putz G, Walch M, Van Eijk M, Haagsman HP,. A spreading technique for forming film in a captive bubble. Biophys J 1998; 75: 2229-2239.
25. Schurch S, Bachofen H, Possmayer F,. Surface activity in situ, in vivo, and in the Captive Bubble Surfactometer. Comp Biochem Physiol A Mol Integr Physiol 2001; 129: 195-207.
26. Gross NJ,. Extracellular metabolism of pulmonary surfactant: the role of a new serine protease. Annu Rev Physiol 1995; 57: 135-150.
27. Lewis JF, Novick RJ, Veldhuizen RAW,. Surfactant in lung injury and lung transplantation. New York: Springer; 1997. pp 1-181.
28. Bernhard W, Mottaghian J, Gebert A, Rau GA, von der Hardt H, Poets CF,. Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am J Respir Crit Care Med 2000; 162: 1524-1533.
29. Bhashyam AR, Wolf MT, Marcinkowski AL, Saville A, Thomas K, Carcillo JA, Corcoran TE,. Aerosol delivery through nasal cannulas: an in vitro study. J Aerosol Med Pulm Drug Deliv 2008; 21: 181-188.
30. Kim SH, Franses EI,. New protocols for preparing dipalmitoylphosphatidylcholine dispersions and controlling surface tension and competitive adsorption with albumin at the air/aqueous interface. Colloids Surf B Biointerfaces 2005; 10: 255-266.